The risk of Coronavirus disease 2019 (COVID-19) in patients with bullous pemphigoid and pemphigus: A population-based cohort study

How does this article integrate into what was already known Patients with BP and pemphigus do not have an increased risk of COVID-19 infection relative to control individuals. Patients with BP may have an elevated COVID-19-associated mortality. How does it change practice? That is, what does the article mean to the practice of dermatology, and what should you do as a result of having read this article? What should change in the way you practice COVID-19-positive BP patients should be followed and monitored closely. Given that the intake of systemic corticosteroids and immunosuppressive adjuvants did not predict worse COVID-19 outcomes, these drugs should not be ceased during the pandemic.本文如何与既往研究认知相契合？大疱性类天疱疮（Bullous Pemphigoid，BP）与天疱疮患者，相较于对照组人群，感染新冠病毒（COVID-19）的风险并未升高；而大疱性类天疱疮患者的新冠相关死亡率可能有所升高。本文将如何改变临床实践？换言之，本文对皮肤科临床工作有何指导价值？阅读本文后，临床医师应采取哪些相应举措？针对新冠病毒检测阳性的大疱性类天疱疮患者，临床随访与监测流程应作出调整：需对患者实施密切的随访与监测。鉴于全身应用糖皮质激素与免疫辅助抑制剂并未导致新冠感染预后恶化，因此疫情期间不应停用此类药物。